NovaBay Pharmaceuticals I...

0.58
0.00 (0.49%)
At close: Apr 24, 2025, 3:56 PM
0.59
0.63%
Pre-market: Apr 25, 2025, 08:30 AM EDT

Company Description

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally.

It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand.

It sells its products through retailers, digital beauty channels, and distributors, as well as online.

The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.

NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc. logo
Country United States
IPO Date Oct 26, 2007
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Justin M. Hall Esq., J.D.

Contact Details

Address:
2000 Powell Street
EmeryVille, California
United States
Website https://novabay.com

Stock Details

Ticker Symbol NBY
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001389545
CUSIP Number 66987P201
ISIN Number US66987P3001
Employer ID 68-0454536
SIC Code 2834

Key Executives

Name Position
Justin M. Hall Esq., J.D. President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
Tommy Law Controller, Interim Chief Financial Officer & Treasurer

Latest SEC Filings

Date Type Title
Apr 22, 2025 8-K Current Report
Apr 15, 2025 4 Filing
Apr 15, 2025 4 Filing
Apr 15, 2025 4 Filing
Apr 15, 2025 4 Filing
Apr 15, 2025 4 Filing
Apr 15, 2025 4 Filing
Apr 15, 2025 4 Filing
Apr 07, 2025 3 Filing
Apr 02, 2025 10-K Annual Report